Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?

PURPOSE: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy. METHODS: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ghazi, Nicola G, Kirk, Tyler Q, Knape, Robert M, Tiedeman, James S, Conway, Brian P
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2010
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2861937/
https://ncbi.nlm.nih.gov/pubmed/20463798
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk